Buprenorphine/naloxone inhibition of remifentanil procedural sedation.
Opioid analgesics are the mainstay of treatment of moderate and severe pain. Remifentanil is an ultrashort acting opioid analgesic used in emergency department (ED)procedural sedation, whereas buprenorphine/naloxone (Suboxone) is an opioid agonist-antagonist combination used in the treatment of addiction-prone individuals. We report here a case of buprenorphine/naloxone inhibition of remifentanil analgesia in a patient undergoing ED procedural sedation.
Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. thomas_gilmore@hotmail.com
Thomas
T
Gilmore
Al
A
Saccheti
Teena
T
Cortese
D000701:Analgesics, Opioid / Q000009:adverse effects*; D002047:Buprenorphine / Q000009:adverse effects*; D016292:Procedural Sedation; D004636:Emergency Service, Hospital; D006801:Humans; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors*; D008297:Male; D009270:Naloxone / Q000009:adverse effects*; D059408:Pain Management / Q000009:adverse effects / Q000379:methods; D010880:Piperidines / Q000037:antagonists & inhibitors*; D000077208:Remifentanil; D014954:Wrist Injuries / Q000601:surgery; D055815:Young Adult
D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives; D010880:Piperidines; D009270:Naloxone; D002047:Buprenorphine; D000077208:Remifentanil